Corcept Therapeutics (CORT) Cash from Financing Activities (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Cash from Financing Activities data on file, last reported at $760000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 101.91% year-over-year to $760000.0; the trailing twelve-month figure through Mar 2026 stood at -$179.8 million (down 165.95% YoY), and the FY2025 full-year result was -$220.4 million, down 677.33% from the prior year.
• Cash from Financing Activities climbed to $760000.0 in Q1 2026, from -$31.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $766000.0 in Q4 2023 to a low of -$145.8 million in Q2 2023.
• A 5-year average of -$24.4 million and a median of -$3.9 million in 2023 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 1355.74% in 2023 and slumped 7230.2% in 2025, its largest moves.
• Tracing CORT's Cash from Financing Activities over 5 years: stood at -$61000.0 in 2022, then surged by 1355.74% to $766000.0 in 2023, then sank by 695.82% to -$4.6 million in 2024, then tumbled by 583.96% to -$31.2 million in 2025, then jumped by 102.43% to $760000.0 in 2026.
• Business Quant data shows CORT's Cash from Financing Activities at $760000.0 in Q1 2026, -$31.2 million in Q4 2025, and -$46.4 million in Q3 2025.